文献速递妇科

林扎戈利治疗症状性子宫腺肌病:一项口服促性腺激素释放激素拮抗剂先导研究

Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study.
PubMed 文献 · Reprod Biomed Online · 2021-10-03

这项单中心、开放标签先导研究纳入8名MRI确诊的子宫腺肌病患者,每日口服林扎戈利200毫克12周后改为100毫克12周。24周时子宫体积较基线缩小32%(P=0.0057),12周时缩小55%(P<0.0001),血清雌二醇被抑制,盆腔痛等症状改善,最常见不良事件为潮热。

要点

  • 每日口服林扎戈利200毫克12周后改100毫克12周,24周子宫体积缩小32%。
  • 治疗12周时子宫体积缩小55%,血清雌二醇在200毫克阶段低于20皮克/毫升。
  • 盆腔痛、痛经、非经期盆腔痛、性交痛、排便痛及生活质量均有改善。

核心结论

  • 每日口服林扎戈利200毫克12周后改为100毫克12周,可缩小腺肌病子宫体积并改善相关症状。

研究设计与样本

  • 单中心、开放标签先导研究,纳入8名经磁共振成像确诊的子宫腺肌病患者,年龄37至45岁。
  • 治疗方案为每日口服林扎戈利200毫克12周,随后每日100毫克12周,共24周。
  • 主要疗效终点为24周时磁共振成像测定的子宫体积变化。

主要发现

  • 基线子宫体积(均值±标准差)为333±250立方厘米。
  • 治疗12周时子宫体积为159±95立方厘米,较基线缩小55%(P<0.0001)。
  • 治疗24周时子宫体积为204±126立方厘米,较基线缩小32%(P=0.0057)。
  • 200毫克林扎戈利治疗12周期间血清雌二醇中位数被抑制至低于20皮克/毫升,100毫克治疗期间维持低于60皮克/毫升。
  • 24周时骨密度平均百分比变化:脊柱-2.4%、股骨颈-1.3%、全髋-4.1%;最常见不良事件为潮热。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does a once-daily regimen of linzagolix, a new oral gonadotrophin-releasing hormone (GnRH) antagonist, given at a fully suppressive dose (200 mg) for 12 weeks, followed by a partially suppressive dose (100 mg) for a further 12 weeks, reduce adenomyotic uterine size and associated symptoms? DESIGN: Eight women (aged 37-45 years) with adenomyosis confirmed by magnetic resonance imaging (MRI) were enrolled in a single-centre, open-label pilot study. The primary efficacy end-point was the change in uterine volume on MRI at 24 weeks. Secondary efficacy end-points included serum oestradiol, overall pelvic pain, dysmenorrhoea, non-menstrual pelvic pain, dyspareunia, dyschezia and quality of life (QoL). Bone mineral density (BMD) was assessed at baseline and 24 weeks. RESULTS: At baseline, uterine volume (mean ± SD) was 333 ± 250 cm3. After 24 weeks, it was 204 ± 126 cm3, a reduction of 32% from baseline (P = 0.0057). After 12 weeks, it was 159 ± 95 cm3, a reduction of 55% (P < 0.0001). Median serum oestradiol was suppressed below 20 pg/ml during the 12 weeks on 200 mg linzagolix, and maintained below 60 pg/ml on 100 mg linzagolix. Improvements in overall pelvic pain, dysmenorrhoea, non-menstrual pelvic pain, dyspareunia, dyschezia and QoL were observed. Mean percentage change in BMD loss at 24 weeks was -2.4%, -1.3% and -4.1% for the spine, femoral neck and total hip, respectively. The most common adverse events were hot flushes. CONCLUSIONS: A once-daily regimen of 200 mg linzagolix for 12 weeks and then 100 mg for another 12 weeks decreased adenomyotic uterine volume and improved associated symptoms.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Donnez J, Donnez O, Brethous M, et al. Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study. Reprod Biomed Online. 2021. PMID: 34799277. doi:10.1016/j.rbmo.2021.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。